3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
21
Breast Neoplasms
19
Prostatic Neoplasms
12
Neuroblastoma
11
Multiple Myeloma
11
Leukemia
11
Leukemia, Myeloid, Acute
10
Lymphoma
9
Lymphoma, Non-Hodgkin
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Breast Neoplasms, Male
8
Glioblastoma
7
Ovarian Neoplasms
6
Myelodysplastic Syndromes
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Fallopian Tube Neoplasms
5
Colorectal Neoplasms
5
Neoplasms
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Chronic-Phase
4
Hodgkin Disease
4
Glioma
4
Carcinoma, Ovarian Epithelial
4
Uveal Melanoma
3
Rhabdomyosarcoma
3
Pancreatic Neoplasms
3
Medulloblastoma
3
Lung Neoplasms
3
Interventions
Temozolomide
93
Radiotherapy
66
Bevacizumab
35
Radiation
22
Carmustine
21
Erlotinib Hydrochloride
17
Chemotherapy, Adjuvant
17
Irinotecan
16
Magnetic Resonance Spectroscopy
13
Radiotherapy, Conformal
11
O(6)-benzylguanine
11
Surgical Procedures, Operative
10
Radiotherapy, Intensity-Modulated
10
sargramostim
9
Sirolimus
9
Imatinib Mesylate
9
Carboplatin
9
temsirolimus
8
motexafin gadolinium
7
Thalidomide
7
Gene Expression Profiling
7
aldesleukin
6
Sorafenib
6
Radiosurgery
6
Immunohistochemistry
6
Hydroxyurea
6
Gefitinib
6
Filgrastim
6
Everolimus
6
Etoposide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gliosarcoma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled